Systemic light chain (AL) amyloidosis is caused by a B-cell (most commonly plasma cell)
clone that produces a toxic light chain that forms amyloid fibrils in tissues and causes …

The treatment of patients with systemic light chain (AL) amyloidosis is a challenge to
hematologists. Despite its generally small size, the underlying clone causes a rapidly …

Systemic immunoglobulin light chain (AL) amyloidosis is a disorder characterized by the
production of clonal serum free light chains that misfold, aggregate, and deposit in vital …

Light chain (AL) amyloidosis is a plasma cell dyscrasia characterized by the pathologic
production of fibrillar proteins comprised of monoclonal light chains which deposit in tissues …

Introduction: The field of systemic amyloidosis is experiencing major advances in diagnostic
and prognostic methods coupled with a growing availability in treatment options. Areas …

Abstract Purpose of Review Light chain (AL) amyloidosis is an insidious progressive
disease which results in significant morbidity and inevitable mortality if not diagnosed and …

The treatment options for systemic light chain amyloidosis (AL) are currently widening in an
unprecedented way, brought about by an expanding arsenal of anti-myeloma therapy as …

The management of light chain (AL) amyloidosis has improved in recent years thanks to
accurate biomarker-based staging systems and response criteria and availability of novel …

Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder
characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in …

Light chain (AL) amyloidosis is caused by a usually small plasma cell clone producing a
misfolded light chain that deposits in tissues. Survival is mostly determined by the severity of …